文献速递细菌感染、耐药与抗菌药物

口服磷霉素转换治疗对比持续静脉β-内酰胺类治疗产ESBL肠杆菌复杂性尿路感染:多中心开放标签随机对照试验

Fosfomycin as Oral Transition Therapy Versus Continued Intravenous β-Lactams for Complicated Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacterales: A Multicenter, Open-Label, Randomized Controlled Trial.
PubMed 文献 · Clin Infect Dis · 2026-01-01

该多中心开放标签随机非劣效试验在韩国四家三级医院纳入299例因产ESBL肠杆菌复杂性尿路感染住院、经3-7天静脉抗生素治疗后病情改善的成人,1:1随机接受口服磷霉素氨丁三醇(3g每日一次)或继续静脉碳青霉烯/β-内酰胺酶抑制剂治疗。口服磷霉素组临床治愈率92.8%,静脉组95.2%(风险差-2.47%,95%CI -7.84至2.89),证实非劣效;微生物学治愈、安全性和30天结局两组相当。

要点

  • 口服磷霉素转换治疗对产ESBL肠杆菌复杂性尿路感染临床治愈非劣效于持续静脉治疗。
  • 两组微生物学治愈率(尿98.0% vs 96.6%;血97.3% vs 97.5%)均高且相近。
  • 口服磷霉素可作为碳青霉烯节约型抗菌药物管理策略用于此类患者。

核心结论

  • 口服磷霉素作为转换治疗对产ESBL肠杆菌复杂性尿路感染非劣效于持续静脉β-内酰胺类治疗。

主要发现

  • 临床治愈率口服磷霉素组92.8%,静脉组95.2%,风险差-2.47%(95%CI -7.84至2.89),确认非劣效。
  • 微生物学治愈率尿培养98.0% vs 96.6%,血培养97.3% vs 97.5%。
  • 安全性和30天结局两组相当。

关键数值与推荐

  • 主要结局临床治愈定义为完成治疗后4天内尿路感染相关症状和体征消退。
  • 口服磷霉素氨丁三醇剂量为3g每日一次。

临床怎么用

  • 对经3-7天静脉抗生素治疗后病情改善的产ESBL肠杆菌复杂性尿路感染住院成人,可考虑转换为口服磷霉素以节约碳青霉烯类。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Extended-spectrum β-lactamase (ESBL)-producing Enterobacterales are an increasing cause of complicated urinary tract infections (UTIs). Reliance on carbapenems to treat these infections accelerates resistance, underscoring the urgent need for effective oral transition options to preserve last-line agents and lessen healthcare burden. METHODS: We conducted a multicenter, open-label, randomized, noninferiority trial at four tertiary hospitals in South Korea (November 2022-June 2025). Adults hospitalized with complicated UTIs due to ESBL-producing Enterobacterales who improved after 3-7 days of intravenous antibiotics were randomized (1:1) to either continue intravenous carbapenem or β-lactam/β-lactamase inhibitor therapy or switch to oral fosfomycin trometamol (3 g once daily). The primary outcome was clinical cure, defined as resolution of urinary tract infection-related symptoms and signs within 4 days after completion of treatment. Secondary outcomes included microbiological cure, readmission, adverse events, and 30-day recurrence. RESULTS: Of the 344 screened patients, 299 were randomized (152 oral fosfomycin; 147 intravenous therapy). Clinical cure occurred in 92.8% of the oral fosfomycin group and 95.2% of the intravenous group (risk difference, -2.47%; 95% CI -7.84 to 2.89), confirming noninferiority. Microbiological cure was similarly high in both groups: urine (98.0% vs 96.6%) and blood (97.3% vs 97.5%). Safety profiles and 30-day outcomes were also comparable. CONCLUSIONS: Oral fosfomycin was noninferior to continued intravenous therapy when used as oral transition therapy for complicated UTIs caused by ESBL-producing Enterobacterales. These findings provide evidence to support oral fosfomycin transition as a carbapenem-sparing antibiotic stewardship strategy for patients with complicated UTIs caused by ESBL-producing Enterobacterales. CLINICAL TRIALS REGISTRATION: KCT0007669.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Seo JW, Kim DY, Yoon Y, et al. Fosfomycin as Oral Transition Therapy Versus Continued Intravenous β-Lactams for Complicated Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacterales: A Multicenter, Open-Label, Randomized Controlled Trial. Clin Infect Dis. 2026. PMID: 42313397. doi:10.1093/cid/ciag345

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。